```html

Nevoid Basal Cell Carcinoma Syndrome (Gorlin‑Gilbert Syndrome)

Overview

Nevoid basal cell carcinoma syndrome (NBCCS), also known as Gorlin‑Gilbert syndrome or Gorlin syndrome, is a rare, inherited genetic disorder that predisposes affected individuals to multiple basal cell carcinomas (BCCs), various developmental anomalies, and an increased risk of certain tumors. It follows an autosomal‑dominant inheritance pattern, meaning a single copy of the mutated gene is enough to cause the condition.

Who is affected? Both males and females are equally likely to inherit the syndrome. Symptoms typically appear in childhood or adolescence, but the age of onset can vary widely. Because the condition is genetic, it can affect people of any ethnicity or geographic location.

Prevalence: NBCCS is estimated to occur in <sup>1</sup>/<sub>5,800</sub> to <sup>1/<sub>10,000</sub> individuals worldwide, though some populations (e.g., certain Native American groups) show a slightly higher frequency.1 The condition is often under‑diagnosed because early skin lesions may be mistaken for ordinary acne or sun‑related spots.</sup>

Symptoms

NBCCS is a multisystem disorder. The signs can be grouped into cutaneous, skeletal, dental, neurologic, and other systemic manifestations.

Cutaneous (Skin) Findings

• Basal cell carcinomas (BCCs): Multiple, often dozens to hundreds of BCCs appear, usually before the age of 30. They may be pink, pearly papules with telangiectasia or raised, ulcerated nodules.
• Palmar/plantar pits: Small, depressible pits on the palms of the hands and soles of the feet; they become more apparent with age.
• Epidermoid cysts: Dome‑shaped, keratin‑filled cysts that can occur on the scalp, face, or trunk.
• Congenital melanocytic nevi: Large pigmented birthmarks that may be present at birth or develop in early childhood.

Skeletal Anomalies

• Jaw cysts (odontogenic keratocysts): Occur in 50‑70% of patients, often causing painless swelling of the jaw.
• Rib anomalies: Bifid, fused, or missing ribs are common; they may be identified on a chest X‑ray.
• Spinal abnormalities: Scoliosis, vertebral fusion, or hemivertebrae.
• Polydactyly or syndactyly: Extra fingers/toes or fused digits, especially of the fifth finger.
• Frontal bossing and macrocephaly: Enlarged forehead and overall head size.

Dental Manifestations

• Large, often cystic, lesions in the mandible or maxilla that can cause tooth displacement.
• Delayed eruption of permanent teeth, missing teeth, or abnormal tooth shape.

Neurologic & Ocular Findings

• Macrocephaly (head circumference >2 SD above the mean).
• Calcification of the falx cerebri: Seen on brain imaging; usually asymptomatic.
• Medulloblastoma: A malignant brain tumor that occurs in 5‑10% of children with NBCCS, often in the cerebellum.
• Eye abnormalities: Hypertelorism (wide-set eyes), cataracts, or coloboma.

Other Systemic Features

• Increased predisposition to ovarian fibromas (women) and cardiac fibromas.
• Hyperkeratosis of the skin on the face and trunk.
• Rarely, developmental delays or learning difficulties.

Causes and Risk Factors

NBCCS is caused by pathogenic variants in genes that are part of the Sonic Hedgehog (SHH) signaling pathway, most commonly the PTCH1 gene on chromosome 9q22.3. Less frequently, mutations are found in SUFU (on chromosome 10) or PTCH2. These genes normally act as tumor suppressors; loss of function leads to uncontrolled cellular proliferation.

Genetic Inheritance

• Autosomal‑dominant: Affected parent has a ~50% chance of passing the mutation to each child.
• De novo mutation: Up to 30% of cases arise from a new mutation in a family with no prior history.

Risk Factors

• Having a first‑degree relative with NBCCS.
• Carrying a pathogenic PTCH1, SUFU, or PTCH2 variant.
• Excessive ultraviolet (UV) exposure can accelerate the development of BCCs, though the underlying mutation is the primary cause.

Diagnosis

Diagnosis is clinical, supported by genetic testing. The major and minor criteria (based on the 1997 and 2005 diagnostic guidelines) help clinicians identify the syndrome.

Clinical Criteria

• Major criteria (need ≥2): Multiple BCCs (or one before age 20), odontogenic keratocysts, palmar/plantar pits, lamellar calcification of the falx cerebri, bifid ribs, first‑degree relative with NBCCS.
• Minor criteria (need ≥2): Macrocephaly, congenital malformations (e.g., cleft lip/palate), cardiac fibroma, ovarian fibroma, medulloblastoma, etc.

Genetic Testing

Sequencing of PTCH1, SUFU, and PTCH2 using a blood sample confirms the diagnosis in >90% of cases. Testing is also recommended for at‑risk family members.

Imaging & Other Tests

• Dental panoramic radiograph (OPG): Detects odontogenic keratocysts.
• Chest X‑ray or CT: Evaluates rib anomalies and pulmonary manifestations.
• MRI of the brain: Screens for medulloblastoma and assesses falx calcification.
• Dermoscopic examination: Helps differentiate early BCCs from benign lesions.

Treatment Options

Because NBCCS affects many organ systems, a multidisciplinary team (dermatology, oral‑maxillofacial surgery, genetics, oncology, ophthalmology, and neurology) is essential.

Skin Cancer Management

• Surgical excision: Standard for isolated BCCs; ensures clear margins.
• Mohs micrographic surgery: Preferred for cosmetically sensitive areas (face) to preserve healthy tissue.
• Topical therapies: Imiquimod or 5‑fluorouracil for superficial BCCs.
• Photodynamic therapy (PDT): Effective for multiple superficial lesions.
• Systemic hedgehog inhibitors: Vismodegib (Erivedge) and Sonidegib (Odomzo) target the SHH pathway and can shrink or halt BCC growth. FDA‑approved for locally advanced or metastatic BCC; they are also used off‑label for extensive NBCCS‑related BCCs. Common side effects include muscle cramps, taste loss, and alopecia.

Oral and Jaw Cysts

• Cyst enucleation or marsupialization: Performed by oral‑maxillofacial surgeons.
• Decompression with regular follow‑up: Reduces recurrence.

Medulloblastoma

• Standard pediatric protocol—surgical resection followed by craniospinal irradiation and chemotherapy.
• Patients with SUFU mutations have a higher medulloblastoma risk; early MRI screening is recommended.

Supportive / Lifestyle Interventions

• Rigorous sun protection (broad‑spectrum SPF 30+ sunscreen, protective clothing, UV‑blocking sunglasses).
• Regular dermatologic surveillance (every 3‑6 months).
• Dental examinations every 6 months to monitor cyst development.
• Genetic counseling for patients and family members.

Living with Nevoid Basal Cell Carcinoma Syndrome

Managing NBCCS is a lifelong commitment, but with proactive care, most people lead active, healthy lives.

Daily Management Tips

• Sun safety: Apply sunscreen 15 minutes before going outdoors; reapply every 2 hours.
• Skin self‑exam: Perform a thorough check of your entire skin surface weekly; use a mirror for hard‑to‑see areas.
• Dental hygiene: Brush twice daily, floss, and schedule semi‑annual dental X‑rays.
• Protective clothing: Wide‑brimmed hats, UPF garments, and gloves reduce UV exposure to hands (where pits often develop).
• Healthy diet & hydration: Antioxidant‑rich foods (berries, leafy greens) may support skin health.
• Psychological support: Join patient advocacy groups (e.g., the Gorlin Syndrome Alliance) for peer support.
• Medication adherence: If on a hedgehog inhibitor, take medication exactly as prescribed; report side effects promptly.

Follow‑up Schedule (example)

Provider	Frequency	Focus
Dermatologist	Every 3–6 months	Skin exam, BCC treatment, sunscreen counseling
Oral‑maxillofacial surgeon	Every 6–12 months	Panoramic X‑ray, cyst monitoring
Genetic counselor	At diagnosis, then as needed	Family planning, cascade testing
Neurologist / Oncologist (pediatric)	Annually (or sooner if symptoms)	MRI for medulloblastoma surveillance
Primary care physician	Yearly	Overall health, vaccinations, comorbidity screening

Prevention

While the genetic mutation cannot be “prevented,” several strategies reduce the number and severity of BCCs and other complications.

• UV avoidance: Early‑morning or late‑afternoon outdoor activities, use of UV‑blocking films on windows.
• Chemoprevention: Some studies suggest oral retinoids (e.g., isotretinoin) lower BCC incidence, but benefits must be weighed against teratogenic risk.
• Smoking cessation: Smoking may worsen skin cancer outcomes.
• Regular monitoring: Early detection of new lesions leads to less invasive treatment.
• Prenatal counseling: For affected individuals planning families, discuss options such as pre‑implantation genetic diagnosis (PGD) to avoid transmission.

Complications

If left untreated or poorly managed, NBCCS can lead to serious health issues.

• Advanced basal cell carcinoma: Invasive growth, disfigurement, or metastasis (rare but reported).
• Mandibular or maxillary destruction: Large odontogenic keratocysts can cause bone loss, facial asymmetry, and dental loss.
• Medulloblastoma: Aggressive brain tumor with potential for cerebellar dysfunction and life‑threatening complications.
• Vision loss: From orbital BCCs or ocular anomalies.
• Psychosocial impact: Chronic skin disease may cause anxiety, depression, or social isolation.
• Pregnancy considerations: Some systemic therapies (e.g., vismodegib) are teratogenic; therapy must be halted before conception.

When to Seek Emergency Care

---

Sources:

1. Mayo Clinic. “Nevoid basal cell carcinoma syndrome.” Updated 2023.
2. National Cancer Institute. “Gorlin syndrome (Nevoid basal cell carcinoma syndrome).” 2022.
3. World Health Organization. “Basal cell carcinoma: Epidemiology.” 2021.
4. Cleveland Clinic. “Hedgehog Pathway Inhibitors for Basal Cell Carcinoma.” 2024.
5. American Academy of Dermatology. “Guidelines of care for basal cell carcinoma.” 2022.

```